Human Anti-VEGFR2 Recombinant Antibody (clone 1121B) (CAT#: PABL-743)

Figure 1 The pro-invasive effect of HUVECs or bone marrow cells on cancer cells.

(A, B) Invasion chamber assay was used to evaluate the invasion of KYSE270 cells attracted by HUVECs in the presence or absence of IMC-18F1 and IMC-1121B. (C, D) The ability of sorted VEGFR1 + and VEGFR2 + bone marrow cells to attract invading KYSE270 cancer cells was determined. Bars, SD; **, P < 0.01, ***, P < 0.001 compared with the cells treated with VEGF and isotype IgG.

Xu, W. , Li, B. , Lam, A. , Tsao, G. , Law, S. , & Chan, K. , et al. (2015). Targeting vegfr-1 and vegfr2-expressing non-tumor cells is essential for esophageal cancer therapy. Oncotarget, 6(3), 1790-805.

Figure 2 KDR-Blocking ELISAs.

(A) 1121B Fab blocking the binding of KDR d1–3-Fc, d1–7-Fc, or d1–7-AP to VEGF-165. Points and error bars represent mean ± SEM of duplicate or triplicate measurements. Curves are nonlinear fits to a single-site inhibition equation, with fixed KD and concentration for the KDR-VEGF interaction as described in Experimental Procedures.

Franklin, M. , Navarro, E. , Wang, Y. , Patel, S. , Singh, P. , & Zhang, Y. , et al. (2011). The structural basis for the function of two anti-vegf receptor 2 antibodies. Structure, 19(8), 1097-1107.

Figure 1 Human Anti-VEGFR2 Recombinant Antibody (PABL-743) in SDS-PAGE

Lane 1: Reducing (SDS-PAGE)
Lane 2: Non-Reducing (SDS-PAGE)